---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-22-000002"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2022-01-26T23:59:59+00:00"
generated_at: "2026-06-27T15:19:45.974116+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Edwards Q4 sales $1.33B (+12% YoY); adjusted EPS $0.51; guides FY22 sales $5.5-6.0B

## Summary
- Q4 sales $1.33B, up 12% (13% underlying); TAVR sales $872M (+12%); TMTT $25M.
- Q4 GAAP EPS $0.53; adjusted EPS $0.51.
- Full year 2021 sales $5.2B (+19%); adjusted EPS $2.22 (+19% YoY).
- FY22 guidance: sales $5.5-6.0B (low double-digit growth); adjusted EPS $2.50-$2.65; Q1 sales $1.27-1.35B.
- Completed enrollment of CLASP IID and EARLY TAVR trials; FDA approved SAPIEN 3 with Alterra.

## SEC filing metadata
- accession: 0001099800-22-000002
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2022-01-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980022000002/0001099800-22-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980022000002/ew-20220126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-22-000002
- JSON: https://secwatch.observer/filing/0001099800-22-000002.json
- Plain text: https://secwatch.observer/filing/0001099800-22-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.